Surgery or radiotherapy is the gold standard treatment for low- to intermediate-risk localized prostate cancer patients. Still, the side effects of the treatment and possible patient comorbidities might hamper patients from allowing these kinds of approaches.
A myriad of molecular-based risk assessment tests derived from serum, urine, and tissue have emerged to improve the specificity for detection and stratification of clinically significant prostate cancer.
Prostate multiparametric magnetic resonance imaging (mpMRI) has emerged as the imaging method best able to detect clinically significant prostate cancer and to guide biopsy.
Some men with early stage (localized) prostate cancer who previously had to choose between active surveillance and aggressive treatment with a greater risk for side effects, now have a new option for treatment, focal therapy.
Prostate cancer screening involves testing for prostate cancer in men who have no symptoms of the disease. This testing can find cancer at an early stage. However, medical experts agree that prostate cancer screening should not be routinely ordered for all men and that screening can lead to both benefits and harms.